Cantel Medical Corp. (NYSE:CMD) EVP Eric W. Nodiff sold 2,868 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $97.55, for a total transaction of $279,773.40. Following the sale, the executive vice president now directly owns 39,102 shares of the company’s stock, valued at $3,814,400.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Cantel Medical Corp. (NYSE:CMD) traded down 1.29% during mid-day trading on Monday, hitting $97.05. 92,739 shares of the stock traded hands. The company has a market cap of $4.03 billion, a price-to-earnings ratio of 56.75 and a beta of 1.25. Cantel Medical Corp. has a 52 week low of $68.19 and a 52 week high of $99.83. The stock has a 50-day moving average of $90.16 and a 200-day moving average of $79.12.
Cantel Medical Corp. (NYSE:CMD) last released its earnings results on Thursday, September 28th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.02. Cantel Medical Corp. had a net margin of 9.27% and a return on equity of 17.60%. The company had revenue of $205.50 million during the quarter, compared to the consensus estimate of $200.32 million. The company’s revenue was up 14.8% on a year-over-year basis. Analysts anticipate that Cantel Medical Corp. will post $2.37 EPS for the current year.
WARNING: This piece was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/10/23/eric-w-nodiff-sells-2868-shares-of-cantel-medical-corp-cmd-stock.html.
CMD has been the subject of several research reports. Zacks Investment Research raised shares of Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical Corp. in a research note on Friday, September 1st. Finally, Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research note on Wednesday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $91.67.
A number of hedge funds have recently added to or reduced their stakes in CMD. Capstone Asset Management Co. purchased a new stake in Cantel Medical Corp. in the 2nd quarter worth approximately $690,000. Bank of Montreal Can bought a new position in shares of Cantel Medical Corp. during the 2nd quarter valued at $248,000. GW&K Investment Management LLC bought a new position in shares of Cantel Medical Corp. during the 2nd quarter valued at $30,121,000. Pennsylvania Trust Co bought a new position in shares of Cantel Medical Corp. during the 2nd quarter valued at $6,590,000. Finally, State of Alaska Department of Revenue bought a new position in shares of Cantel Medical Corp. during the 2nd quarter valued at $558,000. Institutional investors own 83.83% of the company’s stock.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.